Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients-Reference-Cited by-同舟云学术

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Published:2019-06-12 Issue:2 Volume:121 Page:125-130
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Viller Tuxen Ida,Barlebo Ahlborn Lise,Mau-Soerensen Morten,Staal Rohrberg Kristoffer,Cilius Nielsen Finn,Oestrup Olga,Westmose Yde Christina,Richter Vogelius Ivan,Lassen Ulrik

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0491-9.pdf

Reference26 articles.

1. Horstmann, E., McCabe, M. S., Grochow, L., Yamamoto, S., Rubinstein, L., Budd, T. et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N. Engl. J. Med. 352, 895–904 (2005).

2. Schwaederle, M., Zhao, M., Jack Lee, J., Lazar, V., Leyland-Jones, B., Schilsky, R. L. et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms a meta-analysis. JAMA Oncol. 2, 1452–1459 (2016).

3. Bachelot T. D., Catimel G., Ardiet C., Guastalla J. P., Dumortier A., Chauvin F. et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol. 11, 151–156 (2000)

4. Ploquin, A., Olmos, D., Ferté, C., Cassier, P. A., Kramar, A., Duhamel, A. et al. Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit. Rev. Oncol. Hematol. 83, 242–248 (2012).

5. Ploquin, A., Olmos, D., Lacombe, D., A’Hern, R., Duhamel, A., Twelves, C. et al. Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br. J. Cancer 107, 1025–1030 (2012).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP;Journal of Pathology and Translational Medicine;2024-07-15

2. Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP;Cancer Research and Treatment;2023-11-29

3. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients;Translational Lung Cancer Research;2023-06

4. Preoperative Cell-Free DNA (cfDNA) in Muscle-Invasive Bladder Cancer Treatment Outcome;Clinical Chemistry;2023-02-04

5. Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study;Cancers;2022-12-06